Revenue, FY 2025
In EUR, as reported.
#179 by revenue of 180 brands in the benchmark.
ALVAL · Euronext Growth Paris · France
How Valbiotis runs its business, at a glance: €905K in revenue in fiscal 2025 (+417.1%), compared with 66 other omnichannel brands on growth, margins and marketing. 9 fiscal years since 2017 from its annual reports.
The numbers that show how Valbiotis runs: what it keeps from each sale, what it spends to win customers, and what is left. Each card shows the trend and where Valbiotis ranks.
In EUR, as reported.
#179 by revenue of 180 brands in the benchmark.
Revenue against the year before
Above the omnichannel median (+3.6%). Grows faster than 99% of all 174 brands.
Left of each sale after product and delivery costs
Not enough years on record to draw a trend.
Not reported.
Share of revenue spent on marketing and advertising
Spends more than the omnichannel median (9.2%). Spends more than 99% of all 144 brands.
Gross margin minus marketing: what is left for the team, rent and profit
Not enough years on record to draw a trend.
Not reported.
Profit from operations, before interest and tax
Below the omnichannel median (+5.2%). More profitable than 1% of all 178 brands.
Valbiotis: FY 2025. Trend lines: the last 9 fiscal years, dashed line the median omnichannel brand in the same year. Bars: where Valbiotis sits among all 180 brands, from lowest to highest.
For every 100 Valbiotis takes in: what the products cost to make and deliver, what goes to marketing, what runs the company, and what is left as profit.
Product and deliveryMarketingTeam, rent and other costsOperating profitLoss (costs above revenue)
Medians are worked out line by line, so their parts can add up to slightly more or less than 100. Product and delivery is revenue minus gross profit; how much shipping sits there differs by company.
Type in your own numbers to see where you stand against Valbiotis, the median omnichannel brand, and all 180 brands.
| Metric | You | Valbiotis | Gap | Omnichannelmedian | Among all brands |
|---|---|---|---|---|---|
| Revenue growth | – | +417.1% | – | +3.6% | – |
| Gross margin | – | – | – | 52.1% | – |
| Marketing spend | – | 568% | – | 9.2% | – |
| Headroom | – | – | – | 40.3% | – |
| Operating margin | – | -1049.1% | – | +5.2% | – |
Omnichannel brands of a similar size, side by side.
| Brand | Revenue | Growth | Gross margin | Marketing | Headroom | Op. margin |
|---|---|---|---|---|---|---|
| New Nordic HealthbrandsNNH · Europe | SEK 576M | +4.7% | 64.3% | 36.3% | 27.9% | +2.6% |
| SosandarSOS · Europe | £42M | +13.9% | 64% | 5.7% | 58.3% | +0.2% |
| Charlotte's WebCWBHF · US | $45M | -9.1% | 44.2% | 16.3% | 27.9% | -40.2% |
| Online Brands NordicOBAB · Europe | SEK 470M | +28.7% | 57.6% | – | – | -0.8% |
| MADARA CosmeticsMDARA · Europe | €23M | +7.9% | 65.3% | 20.3% | 45% | +1.6% |
| Interactive StrengthTRNR · US | $21M | +197.6% | 30.1% | 24.2% | 5.8% | -72.7% |
| Digital Brands GroupDBGI · US | $5.8M | -33.6% | -2.8% | 393.7% | -396.5% | -699.5% |
| ValbiotisALVAL · Europe | €905K | +417.1% | – | 568% | – | -1049.1% |
| Omnichannel median66 brands | +3.6% | 52.1% | 9.2% | 40.3% | +5.2% |
The 7 omnichannel brands closest to Valbiotis in revenue. Green: above the median, grey: below. Revenue in each company's own currency.
Every fiscal year on record, in EUR. Point at a bar for growth and margins.
| Fiscal year | Revenue | Growth | Gross margin | Marketing | Op. margin | Net margin | Source |
|---|---|---|---|---|---|---|---|
| 2025ends 2025-12-31 | €905K | +417.1% | – | 568% | -1049.1% | -1040.6% | Press release 'Résultats annuels 2025' |
| 2024ends 2024-12-31 | €175K | -96.3% | – | 2491.4% | -5956% | -5728.6% | Press release 'Résultats annuels 2025' |
| 2023ends 2023-12-31 | €4.7M | +502.9% | – | 42.6% | -151.7% | -155.7% | Press release 'résultats annuels 2024' |
| 2022ends 2022-12-31 | €785K | +163.4% | – | 216.9% | -1532% | -1568.4% | Press release 'Valbiotis publie ses résu |
| 2021ends 2021-12-31 | €298K | -90.4% | – | 506.4% | -2844% | -2913.1% | Press release 'Valbiotis publishes its 2 |
| 2020ends 2020-12-31 | €3.1M | +3297.8% | – | 33.3% | -110.2% | -123.8% | Rapport annuel 2020 |
| 2019ends 2019-12-31 | €91K | +15.2% | – | 1618.7% | -5667% | -6048.4% | Rapport annuel 2020 |
| 2018ends 2018-12-31 | €79K | +2533.3% | – | 1340.5% | -6172.2% | -6287.3% | Rapport annuel 2018 |
| 2017ends 2017-12-31 | €3K | – | – | 17766.7% | -79300% | -81433.3% | Rapport annuel 2018 |
Every figure is from Valbiotis's annual reports and results releases; each year links to its document. Amounts in EUR.
Marketing is whatever the company reports as marketing, advertising or selling and marketing, so definitions differ between companies. Rankings compare each brand's latest 12 months (US) or latest fiscal year (Europe).
Notes on this data: IFRS individual accounts, figures published in K€ and converted to euros. Valbiotis was an R&D company until 2024: revenue 2017-2023 is essentially licensing (Nestlé Health Science upfront/milestones), not D2C product sales; own-brand nutraceutical sales started in 2024. Marketing = 'Ventes et Marketing' functional expense line (includes sales force and marketing, not pure advertising). Gross profit not reported (functional P&L; cost of sales line only from 2023 and exceeds revenue). EBITDA not reported in annual figures. 2021 and 2022 tables in the AMF-filed releases are images; figures were read from the release text and the Business Wire distribution of the same company release.
Bratrax connects to your Shopify store and ad accounts and shows you the numbers that decide whether you're making money: profit after ad spend and product costs, which channels bring customers who come back, and where your next dollar should go.
$1 first month · then $99/month flat · no contract